Biotechnology company Tenaya Therapeutics Inc (NASDAQ:TNYA) reported on Monday the addition of June Lee, MD, to its board of directors.
The company added that JJ Kang, PhD will resign from board after five years of service to focus on her current role as CEO of Appia Bio and Venture Partner at The Column Group. Dr Kang has served as the company's board member 2016 as well as interim president for two years.
More recently, Dr Lee was the founder and CEO of Esker Therapeutics as well as executive vice president, chief development officer and chief operating officer of MyoKardia.
Previously, Dr Lee was the therapeutic area head for early clinical development in cardiovascular, metabolism, respiratory and infectious diseases at Genentech.
Currently, Dr Lee is a member of the Advisory Board for Johns Hopkins University Center for Therapeutic Translation, board of director for Eledon Pharmaceuticals Inc and GenEdit, as well as the Scientific Advisory Board for Foresite Labs, respectively.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review